BDX · 8-K · 20260806PR053790
Acquisition / Partnership / Divestiture
BECTON DICKINSON & CO · 2026-08-06 · Importance 65 · Surprise 60 · In source text
BD completed the February 9, 2026 spin-off of its former Biosciences and Diagnostic Solutions business and its combination with Waters Corporation. The transaction eliminated BD’s former Life Sciences segment and left four continuing-operation segments: Medical Essentials, Connected Care, BioPharma Systems and Interventional. BD received a $3.857 billion distribution from the spin-off entity during the first nine months of fiscal 2026 and recorded $73 million of separation-related items during that period.
Key facts
- BD announced a collaboration with EMS (one of Brazil’s leading pharmaceutical companies) to expand access to GLP-1 therapies through a semaglutide launch utilizing BD's Vystra™ Injection Pen platform. source
- The Advanced Patient Monitoring acquisition incurred transaction costs recorded to Integration, restructuring and transaction expense (transaction costs $1 million pre-tax in the three months ended June 30, 2025 and $5 million pre-tax in the nine months ended periods). source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | BD announced a collaboration with EMS (one of Brazil’s leading pharmaceutical companies) to expand access to GLP-1 therapies through a… |